MeSH D008545 - melanoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D018326:Nevi and melanomas
0 Companies
0 Drugs
Success rate
D018358:Neuroendocrine tumors
D012878:Skin neoplasms
D008545:Â
Melanoma
D008546:Experimental melanoma
0 Companies
0 Drugs
Success rate
D018327:Hutchinson's melanotic freckle
0 Companies
0 Drugs
Success rate
D018328:Amelanotic melanoma
D000096142:Cutaneous malignant melanoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Bleomycin | Bleomycin |  | 1996-06-01 |  |  |
| Docetaxel | Docetaxel |  | 2015-09-16 |  |  | |
| Docetaxel | Docetaxel Teva |  | 2010-01-26 |  |  | |
| Docetaxel | Docetaxel Teva Pharma |  | 2011-01-21 |  |  | |
| Temozolomide | Temozolomide Teva |  | 2010-01-28 |  |  | |
| Meitheal Pharmaceuticals | Dacarbazine | Dacarbazine |  | 1998-08-27 |  |  |
| Bleomycin | Bleomycin |  | 2018-04-20 |  |  | |
| Carmustine | Carmustine |  | 2021-08-02 |  |  | |
| Dactinomycin | Dactinomycin |  | 2020-11-13 |  |  | |
| Docetaxel | Docetaxel |  | 2018-08-24 |  |  | |
| Ingenus | Carmustine | Carmustine |  | 2022-06-21 |  |  |
| Docetaxel | Docetaxel | 2036-03-14 | 2022-11-22 |  |  | |
| Mylan | Docetaxel | Docetaxel |  | 2023-05-11 |  |  |
| Docetaxel | Docetaxel Mylan |  | 2012-01-31 |  |  | |
| Temozolomide | Temozolomide |  | 2016-06-29 |  |  | |
| Carmustine | Carmustine |  | 2023-03-03 |  |  | |
| Roche | Cobimetinib | Cotellic |  | 2015-11-20 | $58.637 M | Y2020 |
| Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  | |
| Interferon alfa-2a | Roferon-A |  | 1986-06-04 |  |  | |
| Vemurafenib | Zelboraf | 2026-06-21 | 2011-08-17 |  |  | |
| Cipla | Bleomycin | Bleomycin |  | 2019-03-11 |  |  |
| Sandoz | Docetaxel | Docetaxel |  | 2011-06-29 |  |  |
| Temozolomide | Temozolomide Sandoz |  | 2010-03-15 |  |  | |
| Novartis | Trametinib | Mekinist |  | 2014-06-30 |  |  |
| Dabrafenib | Tafinlar | 2025-06-10 | 2013-05-29 |  |  | |
| Sanofi | Docetaxel | Taxotere |  | 1996-05-14 |  |  |
| Merck Sharp & Dohme | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Pembrolizumab | Keytruda |  | 2014-09-04 | $26,163 M | Q2/23-Q1/24 | |
| Peginterferon alfa-2b | PegIntron |  | 2001-01-19 |  |  | |
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack |  | 2008-06-13 |  |  | |
| Temozolomide | Temodal |  | 1999-01-26 |  |  | |
| Temozolomide | Temodar |  | 1999-08-11 | $215 M | Y2018 | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Peginterferon alfa-2b | ViraferonPeg |  | 2000-05-28 |  |  |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
74%180/244
Phase 2
17%50/286
Phase 3
55%52/94
Approved: 33Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use